Turtle Health Pop-up Clinic
Brookline, Massachusetts, 02445, United States
NCT Number: NCT04784325
The AMH^2 (Anti-Mullerian Hormone - At My Home) study is a head-to-head-to-head validation study aiming to evaluate the concordance of AMH levels found in blood collected via three different routes: collected at-home using the TAP II device, drawn through standard venipuncture techniques, and collected with the ADx card, another at-home collection device widely available on the market for commercial use.
Looking for future studies?
Notify Me20 year–40 year
Female
Interventional
Not applicable
Brookline, Massachusetts, 02445, United States
Today, information regarding fertility potential is challenging to obtain for healthy women; clinically meaningful in-clinic testing is limited by physician availability and patient willingness to undergo testing in-clinic. Meanwhile, at-home hormonal bloodwork relies on the use of an ADx card, and is not widely accepted as clinically reliable by the medical community. The Sponsor is developing a comprehensive home fertility assessment to enable couples to proactively estimate and manage their fertility and family building options. Accurate and reliable at-home AMH testing is necessary to reach this goal.
This study aims to validate the clinical excellence and medical accuracy of blood drawn via the TAP II device relative to a standard in-clinic venipuncture draw and other options available on the market to support emerging telemedicine care models. In doing so, the Sponsor may receive CLIA validation for the TAP II in AMH testing and commercialize a Lab Developed Test.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Study Participants
Inclusion criteria
Exclusion criteria
Two self-administered blood draws through TAP II device
One self-administered ADx card blood draw
One phlebotomist-performed standard venipuncture
Time frame: Lab analysis 72 hours after ADx card/venipuncture/TAP II hand delivery
Evaluate the concordance of the TAP blood collection device after shipment with in-clinic blood collection for AMH.
Time frame: Lab analysis 72 hours after ADx card/venipuncture/TAP II hand delivery
Evaluate the concordance of the TAP blood collection device without shipment with in-clinic blood collection for AMH for control versus venipuncture "ground truth".
Time frame: Lab analysis 72 hours after ADx card/venipuncture/TAP II hand delivery
Evaluate the concordance of the ADx card comparator device with in-clinic blood collection for AMH for control versus venipuncture "ground truth".
Time frame: Lab analysis 72 hours after ADx card/venipuncture/TAP II hand delivery
The number of participants who move to a different risk strata for their age and hormonal birth control status. This will be defined by changing to a different row for their AMH concentration range, treating venipuncture as the "Gold Standard" and comparing the number of women who move rows utilizing their TAP draws or ADx card draw.
Time frame: Survey collected within 3 days of blood draw
Superiority of net promoter score of TAP II device compared to venipuncture as measured by a post-draw survey (calculated as a standard NPS: 9/10 scores - 0-6 scores).
Time frame: Survey collected within 3 days of blood draw
Self-reported pain of different draw methods as measured by a post-draw using the Stanford Pain Scale.
Turtle Health, Inc.
Industry
AMH^2: Anti-Müllerian Hormone - At My Home
Acronym: AMH^2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05443698
Fertility Risk
Boston, Massachusetts, United States
View Trial DetailsNCT04687189
Fertility Risk
Boston, Massachusetts, United States
View Trial Details